# Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases

> **NCT06427642** · NA · RECRUITING · sponsor: **Shandong Qilu Stem Cells Engineering Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Hypoxic-Ischemic Encephalopathy
- Bronchopulmonary Dysplasia
- Short Bowel Syndrome

## Interventions

- **BIOLOGICAL:** Mononuclear cells
- **DEVICE:** Mild hypothermia therapy
- **DEVICE:** Breathing support technique
- **PROCEDURE:** Total parenteral nutrition

## Key facts

- **NCT ID:** NCT06427642
- **Lead sponsor:** Shandong Qilu Stem Cells Engineering Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-01
- **Primary completion:** 2024-05-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06427642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06427642, "Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06427642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*